VK2735 Guide
VK2735: Viking's GLP-1/GIP agonist, in both shot and pill
GLP-1 + GIP
dual agonist, like tirzepatide
Shot + pill
both forms in trials
Not approved
phase 2/3 stage
VK2735 is an investigational GLP-1/GIP dual agonist from Viking Therapeutics, developed in both a weekly injection and a daily oral tablet, and it is one of the most closely watched names in the pipeline. It shares tirzepatide's dual-hormone mechanism, and its early trials drew attention for strong weight loss over short durations, with the oral program adding the prospect of a pill in the same efficacy tier. It is not approved: everything known comes from its trial program, and the numbers, while striking, are early-stage. The side-effect pattern so far is the class-standard gastrointestinal list during dose escalation.
Highlights
Key takeaways
- 01
VK2735 is investigational (Viking Therapeutics), not approved or prescribable; all data is from trials.
- 02
It is a GLP-1/GIP dual agonist, the same receptor combination as tirzepatide, developed in both injectable and oral forms.
- 03
Early trials reported strong weight loss over short durations, drawing significant attention; larger, longer trials are what confirm it.
- 04
The oral program is a key storyline: a pill in the dual-agonist efficacy tier would matter for access.
- 05
Reported side effects are the class GI list (nausea, vomiting, diarrhea) during escalation, mostly mild to moderate.
- 06
Being GLP-1/GIP rather than glucagon-containing, it does not carry the same heart-rate emphasis as the glucagon agents.
VK2735 at a glance: what's known so far
| Aspect | What trials suggest | Context |
|---|---|---|
| Mechanism | GLP-1 + GIP dual agonist | Same combination as tirzepatide |
| Forms | Injectable and oral | Oral is a key differentiator |
| Weight loss | Strong in early trials | Short durations; larger trials pending |
| Developer | Viking Therapeutics | A closely watched pipeline name |
| Side effects | Class-standard GI so far | Escalation-focused |
| Status | Phase 2 / advancing | No approval; timeline unset |
Based on early-phase trial reports and program communications. Early-phase figures are dramatic but least settled; nothing here is prescribing information or a basis for seeking the compound outside trials.
What is VK2735?
VK2735 is an investigational dual agonist that activates the GLP-1 and GIP receptors, the same combination that powers tirzepatide. Developed by Viking Therapeutics, it is being advanced in two forms at once: a weekly injection and a daily oral tablet.
It has become one of the pipeline's most-watched candidates, both because early efficacy looked strong and because a credible oral dual agonist would be a meaningful addition to a field still dominated by injections.
The oral program
The injectable results matter, but the oral VK2735 program is the one that makes people pay extra attention. A pill delivering dual-agonist-tier weight loss would ease the access problems that injections and even the ritual-heavy oral semaglutide leave in place.
It joins a small set of oral hopefuls (alongside orforglipron and oral amycretin) racing to bring top-tier efficacy to a tablet. Whether the oral form holds its early promise through larger trials is the open question.
What early trials suggest
Early-phase trials reported strong weight loss over relatively short durations, which is what put VK2735 on the map. The honest framing: early-phase results in limited populations over short windows are exactly where numbers look most dramatic and are least settled.
Larger, longer trials are what convert promising early data into confirmed, durable efficacy with a fully characterized safety profile. VK2735 is still building that record.
Side-effect profile
The reported side effects are the class standard: gastrointestinal events, nausea, vomiting, and diarrhea, concentrated during dose escalation and mostly mild to moderate. As a GLP-1/GIP agent rather than a glucagon-containing one, it does not carry the same heart-rate emphasis as survodutide, pemvidutide, or retatrutide.
Full safety characterization, as always at this stage, awaits larger trials.
Cautions worth carrying
Expect the incretin-class cautions in any eventual label: pancreatitis vigilance, gallbladder risk with rapid loss, and the thyroid C-cell lineage.
And the market caution, sharp for an early and heavily hyped candidate: there is no legitimate way to obtain VK2735, and anything sold under the name is unregulated gray-market chemistry with no oversight or clinical support.
Worth knowing before the hype carries you
- VK2735 is investigational: no approval, no prescribing information yet
- Anything sold as VK2735 is unregulated gray-market chemistry
- Early-phase numbers are dramatic but least settled; larger trials decide
- The full safety profile is not yet characterized
- Incretin-class cautions (pancreatitis, gallbladder, thyroid C-cell) are expected to apply
- Approved options exist today; the horizon is not a treatment plan
How early is it?
Early enough that timelines are speculative: VK2735 is advancing through trials, not near a pharmacy shelf. Early promise sometimes reads differently at scale, which is what the larger programs will settle.
Treat it as an exciting horizon, not a near-term option. The move for anyone weighing the future is the same as always: get the habits that make any of these drugs work (protein, training, tracking) solid on whatever you and your prescriber choose now. DoseLog carries them to whatever you switch to later.
FAQ
Frequently asked questions
What is VK2735?
An investigational GLP-1/GIP dual agonist from Viking Therapeutics, the same receptor combination as tirzepatide, developed in both injectable and oral forms. Early trials reported strong weight loss; it is not approved.
Is there an oral VK2735?
Yes, an oral tablet is in development alongside the injection, which is a key reason the drug draws attention: a pill in the dual-agonist efficacy tier would matter for access. Its early promise still needs larger-trial confirmation.
What are VK2735's side effects?
Trials so far report the class-standard GI list (nausea, vomiting, diarrhea) during dose escalation, mostly mild to moderate. As a GLP-1/GIP agent it does not carry the heart-rate emphasis of the glucagon-containing drugs.
When will VK2735 be available?
Not soon: it is advancing through trials with a speculative timeline, and needs larger, longer studies before any regulatory submission. Anything sold as VK2735 now is unregulated and unsafe.
Track your GLP-1 journey on one quiet line.
Log your shot, injection site, meals, and side-effect severity together, and walk into your next appointment with a week-by-week picture instead of a guess.
Sources
- 1.Viking Therapeutics VK2735 phase 1/2 trial reports (injectable and oral programs). Find on PubMed ↗
- 2.Company communications on VK2735 development stage and design. Find on PubMed ↗
- 3.Reviews of GLP-1/GIP dual-agonist pharmacology. Find on PubMed ↗
This guide is for general education and is not medical advice. It doesn't account for your personal medical history, other medications, or your individual situation, and it doesn't replace a conversation with your doctor or pharmacist. Do not start, stop, or change the dose of GLP-1 or any medication based on what you read here. If you think you have a medical emergency, call your local emergency number. DoseLog is a tracking app; drug and company names are used factually under nominative fair use, and DoseLog is not affiliated with, endorsed by, or sponsored by any manufacturer mentioned.
Keep reading
CagriSema Guide
CagriSema: semaglutide plus amylin, and what trials report
Survodutide Guide
Survodutide: the GLP-1/glucagon dual agonist in late trials
Mazdutide Guide
Mazdutide: the GLP-1/glucagon agonist approved first in China
Amycretin Guide
Amycretin: the GLP-1/amylin combo in oral and injectable trials